Rate My Professor Shubhra Sinha

Dr. Shubhra Sinha serves as a Postdoctoral Fellow in the Department of Physiology at the University of Otago, within the Faculty of Biomedical Sciences and as part of Heart Otago. She earned her BSc, MSc, and PhD in Pharmaceutical Biology. Her current research investigates the role of microRNAs in diabetic ulcers and the development of biodegradable patches for treating chronic non-healing diabetic ulcers. Previously, she worked as an Assistant Research Fellow in the School of Pharmacy at the University of Otago, where she focused on formulating inhalable dry powder delivery systems for respiratory pathogens. Her pharmaceutical research encompasses spray-drying techniques to create stable, aerosolizable powders for treating infections such as SARS-CoV-2, multidrug-resistant tuberculosis, latent tuberculosis, Pseudomonas aeruginosa lung infections, and chronic obstructive pulmonary disease. This includes studies on combination therapies, chemical stability, in vitro characterization, and safety assessments.

Sinha has co-authored over 20 peer-reviewed publications demonstrating her contributions to pharmaceutical sciences and physiology. Key works include 'Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitro' (Antimicrobial Agents & Chemotherapy, 2025), 'Inhalable spray-dried dry powders combining ivermectin and niclosamide to inhibit SARS-CoV-2 infection in vitro' (International Journal of Pharmaceutics, 2025), 'Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis' (2024), 'Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization' (International Journal of Pharmaceutics, 2023), 'Spray-Dried Inhalable Microparticles Combining Remdesivir and Ebselen against SARS-CoV-2 Infection' (2023), 'Inhalable Combination Powder Formulations for Treating Latent and Multidrug-Resistant Tuberculosis' (Pharmaceutics, 2023), and 'Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder' (2022). She has presented her findings at conferences, including verbal presentations on microRNA modulation in diabetic wound healing at the BMS Postgraduate Symposium (2024) and posters on smart bioscaffolds for diabetic foot ulcers and conductive nanomatrices for cardiovascular tissue engineering at the New Zealand Medical Sciences Congress (2024). Her publications have garnered over 400 citations.